Featured News See All July 18, 2026 REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting July 17, 2026 REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants July 16, 2026 REGENXBIO Announces Proposed Public Offering of Common Stock Year All20262025202420232022202120202019201820172016201520142013201220112009 Jul 18, 2026 REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting Jul 17, 2026 REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants Jul 16, 2026 REGENXBIO Announces Proposed Public Offering of Common Stock Jun 29, 2026 REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone Jun 24, 2026 REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026 Jun 22, 2026 REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II May 18, 2026 REGENXBIO to Participate in Upcoming Investor Conferences
Jul 18, 2026 REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting
Jun 29, 2026 REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone
Jun 24, 2026 REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026
Jun 22, 2026 REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II
